Boston Scientific Logo
US1011371077
884113
BSX

Boston Scientific

Loading quotes...

Forecast

The analysts' average price target is +57,07€ (+42,07%). The median is +54,50€ (+35,67%).

Buy
  38
Hold
  6
Sell
  0

  • Boston Scientific's supply chain disrupted worldwide by cyberattack

    Boston Scientific reports a cyberattack discovered on August 25 that has affected information systems and business applications, causing disruptions to order processing and shipping worldwide. Employees at one site in Ireland were sent home. The company has brought in external cybersecurity experts and is working on restoration, but cannot say when full operations will resume; the extent of operational and financial damage remains unclear. » More on golem.de


  • Boston Scientific cyberattack disrupts global operations and order processing

    Boston Scientific said a cyberattack uncovered Tuesday is disrupting its global information systems and business applications, including systems used to process and ship customer orders. The company has engaged outside cybersecurity experts to investigate and contain the threat while working to restore affected functions, but a full recovery timeline is unknown. Shares fell as much as 6% in early trading following the disclosure. » More on cbsnews.com


  • Boston Scientific weighed by weaker Watchman results and lowered 2026 guidance

    Boston Scientific's shares fell after Q2 results as U.S. Electrophysiology and Watchman missed consensus and management cut 2026 organic sales growth guidance to 10–11%. CHAMPION-AF data met endpoints but failed to act as a positive catalyst for the stock. TCW said the market may be overly discounting Boston Scientific's long-term earnings growth, but the position remains under review. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics
In 2022, Boston Scientific has already paid +0,26€ in dividends. The last payout was in March 2022.

Financials

In the last quarter, Boston Scientific had revenue of +4,77B€ and net profit of +794,72M€
(EUR) Jun 2026
YoY
Revenue +4,77B 11,05%
Gross profit +3,37B 16,06%
Net profit +794,72M 18,12%
EBITDA +1,22B 4,94%

Fundamentals

Metric Value
Market capitalization
+61,45B€
Number of shares
1,49B
52-week high/low
+93,97€ - +36,22€
Dividends No
Beta
0,57
P/E ratio
+19,42
PEG ratio
+0,42
P/B ratio
+2,86
P/S ratio
+3,41

Company profile

Die Boston Scientific Corporation entwickelt, produziert und vertreibt weltweit medizinische GerĂ€te fĂŒr den Einsatz in verschiedenen interventionellen medizinischen Fachgebieten. Das Unternehmen ist in drei Segmenten tĂ€tig: MedSurg, Rhythm and Neuro, und Cardiovascular. Das Unternehmen bietet GerĂ€te zur Diagnose und Behandlung von Magen-Darm- und Lungenerkrankungen, GerĂ€te zur Behandlung verschiedener urologischer und pelviner Erkrankungen, implantierbare Kardioverter und implantierbare Herz-Resynchronisations-Therapie-Defibrillatoren, Herzschrittmacher und implantierbare Herz-Resynchronisations-Therapie-Schrittmacher sowie Remote-Patienten-Management-Systeme. DarĂŒber hinaus bietet das Unternehmen Medizintechnologien zur Diagnose und Behandlung von Herzrhythmusstörungen an, darunter 3D-Kardio-Mapping- und Navigationslösungen, Ablationskatheter, Diagnosekatheter, Mapping-Katheter, intrakardiale Ultraschallkatheter, EinfĂŒhrschleusen und anderes Zubehör, RĂŒckenmarkstimulatorsysteme fĂŒr die Behandlung chronischer Schmerzen, indirekte Dekompressionssysteme und Systeme zur Tiefenhirnstimulation. DarĂŒber hinaus bietet das Unternehmen Produkte fĂŒr die interventionelle Kardiologie an, darunter medikamentenfreisetzende Koronarstentsysteme zur Behandlung der Koronararterienerkrankung, Produkte fĂŒr die perkutane Koronarintervention zur Behandlung von Atherosklerose, Katheter fĂŒr die intravaskulĂ€re Ultraschallbildgebung, GerĂ€te fĂŒr die fraktionierte Flussreserve und Systeme fĂŒr den Einsatz in Koronararterien und Herzkammern sowie in verschiedenen peripheren GefĂ€ĂŸen und strukturelle Herztherapien. DarĂŒber hinaus bietet das Unternehmen Stents, Ballonkatheter, DrĂ€hte und Atherektomiesysteme zur Behandlung von Arterienerkrankungen, Thrombektomie- und akustische Impulsthrombolysesysteme, DrĂ€hte und Stents zur Behandlung von Venenerkrankungen sowie periphere EmbolisationsgerĂ€te, radioaktive MikrosphĂ€ren, Ablationssysteme, Kryotherapie-Ablationssysteme und Mikro- und Drainagekatheter zur Behandlung von Krebs. Das Unternehmen wurde 1979 gegrĂŒndet und hat seinen Hauptsitz in Marlborough, Massachusetts.

Name
Boston Scientific
CEO
Michael F. Mahoney
Headquarters Marlborough, ma
USA
Website
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO
11/19/2019
Employees 59.000

Ticker symbols

Exchange Symbol
NYSE
BSX
London Stock Exchange
0HOY.L
XETRA
BSX.F
Frankfurt
BSX.F
DĂŒsseldorf
BSX.DU
Milan
1BSX.MI
London
0HOY.L
SIX
BSX.SW
MĂŒnchen
BSX.MU
Wien
BSXC.VI
đŸȘ

Parqet  uses cookies. Learn more